Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reduong this burden ABSTRACT Two guinea pig models were used to study the anticonvulsant With the lower dose of atropine, seizure occurrence increased potency of diazepam, midazolam, and scopolamine against to virtually 100% for all agents; the time to seizure onset deseizures induced by the nerve agents tabun, sarin, soman, creased for sarin, cyclosarin, and VX; the signs of nerve agent cyclosarin, O-ethyl S-(2-(diisopropylamino)ethyl)methylphosintoxication were more severe; and coma resulted frequently phonothioate (VX), and 0-isobutyl S-(2-diethylamino)ethyl)-with cyclosarin. The anticonvulsant ED 50 doses for scopolmethyl phosphonothioate (VR). Animals instrumented for elec-amine or diazepam were, in general, not different between the troencephalogram recording were pretreated with pyridostigtwo models, whereas the anticonvulsant ED,, values of midamine bromide (0.026 mg/kg i.m.) 30 min before challenge with zolam increased 3-to 17-fold with the lower atropine dose. 2 x LD 50 (s.c.) of a nerve agent. In model A, atropine sulfate (2.0 Seizure termination times were not systematically effected by mg/kg i.m.) and pyridine-2-aldoxime methylchloride (2-PAM; the different doses of atropine. The order of anticonvulsant 25.0 mg/kg i.m.) were given 1 min after nerve agent challenge, effectiveness within each model was scopolamine Ž-midazoand the tested anticonvulsant was given (i.m.) 5 min after sei-lam > diazepam. The findings indicate that the dose of atropine zure onset. In model B, a lower dose of atropine sulfate (0.1 given as antidotal therapy can significantly influence measures mg/kg i.m.) was given along with 2-PAM 1 min after nerve agent of nerve agent toxicity and responsiveness to anticonvulsant challenge, and the anticonvulsant was given at seizure onset. therapy.
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The potential for exposure to nerve agents exists on the (PB), shields a fraction of cholinesterase in the periphery battlefield and as a terrorist threat (e.g., 1995 Tokyo subway from irreversible inhibition by the nerve agents (Berry and incident). Nerve agent exposure causes a progression of toxic Davis, 1970; Dirnhuber et al., 1979) . In the event of nerve signs (hypersecretions, muscle fasciculations, tremors, con-agent poisoning, immediate treatment with an anticholinvulsions, and respiratory distress) that are due to inhibition ergic drug, such as atropine sulfate, will antagonize the efof acetylcholinesterase (AChE) by the agent and the subse-fects of excess ACh at muscarinic receptor sites, and an quent increase in the concentration of the neurotransmitter oxime, such as pyridine-2-aldoxime methylchloride (2-PAM), acetylcholine (ACh) and hyperstimulation of the cholinergic is used to reactivate inhibited AChE (Moore et al., 1995;  system at central and peripheral sites (Taylor, 2001) . A com -Taylor, 2001 ). bined regimen of prophylaxis and therapy is the most effecThis regimen, however, does not prevent nerve agenttive medical countermeasure for dealing with the threat of induced seizures. Prolonged epileptiform seizures in a nerve agent poisoning to military personnel (Moore et al., nerve agent casualty can produce irreversible brain dam-1995; Sidell, 1997; Aas, 2003) . Pretreatment with carbamate age (McDonough et al., 1995; Shih et al., 2003) that can cholinesterase inhibitors, such as pyridostigmine bromide result in long-term deficits in cognitive function and behavior. Concomitant administration of an anticonvulsant
The opinions or assertions contained herein are the private views of the drug such as diazepam is considered essential to optimize authors and are not to be construed as reflecting the views of the Department the regimen of carbamate pretreatment plus atropine and of the Army or the Department of Defense.
oxime therapy for severely exposed casualties (Dunn and Article, publication date, and citation information can be found at httpJ/jpet.aspetjournals.org. Sidell, 1989; Aas, 2003) . However, i.m. diazepam produces doi:10.1 124/jpet.106.111252. inconsistent bioavailability, it is slow to act, and it can ABBREVIATIONS: AChE, acetylcholinesterase; ACh, acetylcholine; PB, pyridostigmine bromide; 2-PAM, pyridine-2-aldoxime methylchloride; GA, tabun, ethyl N,N-dimethyl phosphoramidocyanidate); GB, sarin, isopropyl methylphosphonofluoridate; GD, soman, pinacolyl methylphosphonofluoridate; GF, cyclosarin, cyclohexylmethyl phosphonofluoridate; VX, O-ethyl S-(2-(diisopropylamino)ethyl)methylphosphonothioate); VR, 0-isobutyl S-(2-diethylamino)ethyl)methyl phosphonothioate); pyridostigmine bromide; EEG, electroencephalogram.
provide less than total protection against the neuropathoto administer anticonvulsant treatment (10 mg of diazelogical consequences of nerve agent exposure (Hayward et pam; convulsant antidote, nerve agent) at the first sign of al ., 1990; McDonough et al., 1995) . Thus, there has been an seizures. Therefore, model B (Fig. 1, bottom) was develactive research effort to find better drugs to treat nerve oped, where 0.1 mg/kg atropine was given along with 25 agent-induced seizures. mg/kg 2-PAM 1 min after nerve agent challenge, and the In our previous studies, anticonvulsant ED 5 0 values of test anticonvulsant drug was given at the time of seizure diazepam, midazolam, and several anticholinergics to anonset. Model B closely mimics the doses and timing of tagonize seizures produced by a number of nerve agents, current United States military pretreatment and therapy such as tabun (GA), sarin (GB), soman (GD), cyclosarin regimen in the event of nerve agent exposure. The present (GF), VX, or VR, were determined in a guinea pig model study determined the potency of diazepam, midazolam, McDonough, 1999, 2000; Shih et al., 2003) . In and scopolamine in terminating seizures induced by GA, this original model (designated here as model A; Fig. 1 , GB, GD, GF, VX, or VR in this refined model B. A compartop), guinea pigs were pretreated with PB and then chalison was then made with respect to these two doses of lenged with 2 x LD 5 0 of a nerve agent, followed 1 min later atropine on a number of parameters: seizure occurrence, by 2-PAM (25 mg/kg i.m.) and atropine sulfate (2.0 mg/kg latencies for seizure onset, time to seizure termination, i.m.) therapy. The drug tested for anticonvulsant activity 24-h lethality, and potency of anticonvulsant drugs. was given (i.m.) 5 min after the onset of seizures. When given 5 min after seizure onset, atropine could terminate nerve agent-induced seizures, even though the anticonvulMaterials and Methods sant ED 5 0 required was high (i.e., -10.0 mg/kg for most Subjects. Male Hartley guinea pigs [Crl: (HA) BR COBS; Charles nerve agents) McDonough, 1999, 2000; River Laboratories, Inc., Kingston, NY], weighing 250 to 300 g, al., 2003) . Thus, the inclusion of 2.0 mg/kg atropine as part served as subjects. Upon arrival, the animals were quarantined for a of the immediate treatment with 2-PAM may have overesweek and tested for evidence of disease. They were individually timated the efficacy of the tested anticonvulsant drugs.
housed in polycarbonate cages in temperature-(21 _-2°C) and huFurthermore, a single nerve agent antidote kit (the MARK midity-controlled (50 ± 10%) animal quarters maintained on a 12-h I; Meridian Medical Technologies, Columbia, MD) contains light-dark full-spectrum lighting cycle with lights on at 6:00 AM.
autoinjectors containing 2 mg of atropine and 600 mg of Laboratory chow and water were freely available whenever the anautoinjco eacnmilitainn 2 e me cimals were in home cages. Research was conducted in compliance 2-PAM, and each military service member carries three with the Animal Welfare Act and other Federal statutes and regu-MARK I kits. After a severe nerve agent exposure, three lations relating to animals and experiments involving animals and MARK I nerve agent kits are supposed to be administered adheres to principles stated in the Guide for the Care and Use of to the casualty by his or her buddy or a medic. The delivLaboratory Animals (National Research Council, 1996 less steel screw electrodes using previously described procedures before challenge with 2 x LD.o of a nerve agent s.c., followed 1 min later (Shih and McDonough, 1999; Shih et al., 2003) . by 2-PAM (25 mg/kg i.m.) and atropine (2.0 mg/kg i.m.) therapy. The Experimental Procedure. On the day of the experiment, guinea drugs tested for anticonvulsant activity were given (i.m.) 5 min after the pigs were placed in individual recording chambers and continuously onset of seizures. In model B (bottom), used in this study, guinea pigs monitored for EEG activity. EEG recordings were made using amwere pretreated with PB 30 min before challenge with 2 x LD 50 of a nerve agent, followed 1 min later by 2-PAM (25 mg/kg i.m.) and atropine (0.1 plifiers and QND software supplied by Neurodata, Inc. (Pasadena, mg/kg i.m.). The anticonvulsant treatment was given immediately follow-CA) (low-frequency filter, 0.3 Hz; high-frequency filter, 40 Hz; and ing EEG seizure onset, sampling rate, 128 Hz) and displayed on a computer monitor. After a 15-min recording baseline EEG, animals received a dose of PB nerve agent, the proportion of animals surviving as a function of (0.026 mg/kg i.m.) to produce 20 to 30% whole blood cholinesterase successful control of the seizure, and the incidence of neuropatholinhibition (Lennox et al., 1985) . Thirty minutes later, animals were ogy as a function of seizure control all were evaluated using the challenged s.c. with 2 x LD 50 of GA (240 gg/kg), GB (84 jig/kg), GD Chi-square procedure with Yates correction (Winer, 1971) . In all (56 tig/kg), GF (114 pg/kg), VX (16 pg/kg), or VR (22.6 jig/kg). One of the statistical analyses, P < 0.05 was considered significant. minute after nerve agent challenge, the animal was treated with atropine sulfate (0.1 mg/kg i.m.) plus 2-PAM (25 mg/kg i.m.). This dose of 2-PAM approximates the total dose of 2-PAM in three autoResults injectors (600 mg per injector) given to a 70-to 75-kg human. The Seizure Occurrence. The percentage of seizure occur-0.1-mg/kg dose of atropine sulfate approximates the total dose of rence was approximately 100% in GA-, GD-, GF-, and VRatropine sulfate in the three autoinjectors (2.0 mg per injector) given to a 70-to 75-kg human. Immediately (usually within 15 s) after the exposed guinea pigs with either dose of atropine. When the onset of EEG seizure activity, diazepam, midazolam, or scopolamine atropine dose was lowered from the 2.0-to 0.1-mg/kg dose, was given intramuscularly, seizure occurrence increased significantly (P < 0.001) in anAnimals were observed continuously for the 1st h following expoimals exposed to GB [from 86% (n = 100) to 100% (n = 85)] sure and treatment and periodically thereafter for at least 6 h. EEG and VX [from 51.5% (n = 202) to 95.4% (n = 87)]. was recorded continuously throughout this time and for another 30 Seizure Onset. Seizure onset times (in minutes) after 2 x min at 24 h after exposure. Seizure onset was operationally defined LDo of a nerve agent are shown in Fig. 2 . The seizure onset as the appearance of Ž-10 s of rhythmic high-amplitude spikes or times (mean ± S.E.M.) were significantly shorter (P < 0.01) sharp wave activity in the EEG tracing. Each animal was rated as when the dose of atropine was lowered (2.0 and 0.1 mg/kg, having the seizure terminated (OFF) or not terminated (NOT OFF) respectively) in animals exposed to GB . However, times to seizure onset was recorded 24 h after nerve agent exposure. Animals that survived remained constant between the two doses of atropine sulfate 24 h were euthanized with an overdose of sodium pentobarbital (75 in GA-, GD-, and VR-exposed animals. mg/kg i.p.) and then perfused through the aorta with saline, followed Seizure Termination. Seizure termination times (in by 10% neutral-buffered formalin. minutes) after 2 x LD 5 o of nerve agent are shown in Fig. 3 . The brain was blocked, embedded in paraffin, cut 6 to 10 gim thick, Terminations were significantly different (longer) when the stained with hematoxylin and eosin, and then evaluated by a boardatropine sulfate dose was lowered from the 2.0-mg/kg to the certified pathologist who was unaware of the experimental history of 0.1-mg/kg dose of atropine only in the GF-exposed animals a given subject. The procedures and criteria used for pathological that were treated with diazepam (14.18 ± 6.80 and 68.74 _ evaluation have been published previously (McDonough et al., 1995, 14.05), but they remained the same in midazolam (10.69 ÷ 2000; Shih et al., 2003) . In brief, six brain areas (cerebral cortex, pyriform cortex, amygdala, hippocampus, thalamus, and caudate/ 5.00 and 29.47 _-18.35) and scopolamine (31.50 ± 8.13 and putamen) were evaluated in each animal, and each area was rated on 21.47 ± 8.13) treatment groups. All other termination times a scale from 0 (no damage) to 4 (severe, >45% tissue involvement) for were statistically equivalent for a given treatment with a neuropathological damage. In addition to the individual brain areas, given nerve agent tested between the two doses (2.0 or 0.1 a total brain lesion score was obtained for each animal by summing mg/kg) of atropine sulfate. Another notable difference, when the scores of the six areas.
the results of these two guinea pig models were compared, Data Analysis. Dose-effect curves and the median effective was the significantly more rapid action of midazolam than of dose (ED 5 0 ) for anticonvulsant activity of each individual drug diazepam in terminating GA-, GD-, and VR-induced seizure were determined by probit analysis (Bliss, 1952) drugs were also compared among different nerve agents. Laten-GA GB GD GF VX VR cies for seizure onset between the different nerve agents were not Nerve Agent normally distributed, and they were evaluated using the Kruskal- Fig. 2 . The time (in minutes) to onset of EEG seizure following 2 X LD5,, Wallis analysis of variance on ranks followed by Dunn's multiple of nerve agents in guinea pig models (see Fig. 1 ), where atropine was comparison test. Latencies for seizure terminations were evalueither 0.1 or 2.0 mg/kg i.m. The group size range was 85 to 109. Seizure onset times (in minutes) were significantly (P < 0.01) decreased in GB-, ated using both one-and two-way analysis of variance procedures GF-, and VX-treated animals when the atropine sulfate dose was lowered followed by Tukey's multiple comparison tests. The differences from 2.0 to 0.1 mg/kg. *, P < 0.05 compared between 0.1 and 2.0 mg/kg between proportions of animals surviving challenge with each atropine. lowering the dose of atropine from 2.0 to 0.1 mg/kg, the Toxicity and Lethality. The signs of nerve agent intoxica-24-h lethality increased significantly (P < 0.01) when mition were lacrimation, salivation, rhinorrhea, muscle fascicula-dazolam was used as treatment after GF (23.7 and 60.0%), tions, and tonic-clonic convulsions. These signs were more se-VX (4.6 and 26.7%), and VR (20.8 and 61.3%) and with vere after 0.1 mg/kg atropine sulfate for GA, GB, GF, VX, and diazepam as treatment after GB (0.0 and 25.0%), GF (3.3 VR than with 2.0 mg/kgatropine. However, signsofintoxication and 75.8%), and VR (8.3 and 36.0%). The 24-h lethality were not changed in the GD studies when the atropine sulfate remained statistically equivalent, regardless of atropine was lowered to 0.1 mg/kg. Shortly after agent administration dosage for the diazepam treatment of GA, GD, and VX, for (5-10 min), GF induced a coma in some animals. The coma was midazolam treatment of GA, GB, and GD, and for all nerve a physical state in which respiration rate lowered to a point agents after scopolamine. where the animal grew cyanotic, and EEG activity decreased in As reported previously for the higher dose of atropine in amplitude to a point where it could not be detected; some model A (Shih et al., 2003) , overall there was a strong animals died after reaching this state, whereas in others, res-relationship between the control of seizure activity and piration rate progressively increased, cyanosis was resolved, protection against nerve agent-induced lethality with the and EEG activity resumed. GF-induced coma occurred in 19.8% lower dose of atropine in model B. Only 10% (n -25) of the of animals in the 2.0 mg/kg atropine model, whereas in the 0.1 animals that had their seizures stopped by the anticonvulmg/kg atropine sulfate model, the occurrence of coma increased sant treatment died within 24 h, whereas 52%, (n = 129) significantly to 56.2%.
animals died within 24 h if drug treatment failed to stop The effects of anticonvulsant treatment on 24-h lethality seizures. This difference was highly significant (X" -95.8, GA, GB, GD, GF, VX, and VR was 14-, 13-, 5-, 18-, 15-, and against all of the nerve agents. Although two variables 3-fold, respectively. Diazepam as a treatment resulted in an were changed in model B, atropine dose and timing of anticonvulsant ED 50 that was decreased when the atropine anticonvulsant administration, the data strongly indicate sulfate dose was lowered from 2.0 to 0.1 mg/kg in VR by 2-fold that the lower atropine dose contributed most to the ob-(2.45 versus 1.07 mg/kg), but it remained the same in GA, served differences between the two models. Atropine dose GB, GD, and VX. The anticonvulsant ED 5 o for diazepam to was the only variable that could influence seizure inci-GF was also apparently decreased when the atropine sulfate dence and time of seizure onset. Earlier anticonvulsant dose was lowered from 2.0 to 0.1 mg/kg, but it was not administration would be expected to improve clinical outstatistically significant. The anticonvulsant ED,, for scopol-come and enhance anticonvulsant effectiveness, but these amine was not affected by the atropine sulfate doses for GD, effects were not seen in the results with model B. GF, VX and VR, but was significantly increased for GA (0.04
100-
When the results with model B were compared with versus 0.13 mg/kg; 3-fold) and GB (0.01 versus 0.07 mg/kg; those of model A, there were some predictable differences. 7-fold) when the atropine sulfate dose was lowered from 2.0 With the lowered atropine dose there was a shortened to 0.1 mg/kg. latency to seizure onset and an increased frequency of Neuropathology. All of the nerve agents were capable of seizure occurrence when either GB or VX were the chalproducing neuropathology under the conditions of this study lenge agents, and seizure latency was also decreased for model (model B; Fig. 1 ). As reported earlier for the higher GF. However, the latency to seizure onset was virtually the dose of atropine in model A (Shih et al., 2003) , there was a same between these two models in the case of GA, GI), and strong relationship between the control of seizure activity VR challenge, and the frequency of seizure occurrence for and both the incidence and severity of brain pathology with GA, GD, GF, and VR was already near 100% for with the the lower dose of atropine in model B. Significantly fewer high dose of atropine. numbers of animals in which the seizures were controlled by
In model A, we found that, for GD and VX, the seizure drug treatment displayed brain pathology (71 of 215; 33%) occurrence was 100 and 56%, respectively, the time to compared with the animals where seizures were not con-seizure onset was 8.1 and 20.8 min, respectively, and the trolled by drug treatment (97 of 119; 82%) (X 2 = 70.1, df = 1, anticonvulsant ED 50 for atropine was 11.8 and 4.0 mg/kg, P < 0.001). Moreover, total brain lesion scores were less in respectively (Shih et al., 2003) . The latter indicated that animals in which seizures were controlled by drug treatment significantly lower atropine doses are required to treat (mean = 2.54) compared with those in which seizures were VX-induced seizure activity than GD-induced seizure acnot controlled (mean = 8.98). As was with previously studied tivity in the therapeutic model. In model B, whereas the model A, the basic lesion was one of neuronal necrosis (see latency to seizure and frequency of seizure occurrence for Fig. 5 in Shih et al., 2003 for examples of the pathology). VX were changed, these parameters were not changed for There was no qualitative difference in the appearance of a GD. The differences observed between GD and VX in these lesion nor the brain areas affected between the two models, two models were of particular interest. They may possibly among the different nerve agents, or among the different be explained by the different doses of atropine, the differtreatment drugs. ent physical properties of the nerve agents, and the different responses of GD and VX to the oxime 2-PAM. It is well documented that the GD-AChE complex ages rapidly and that it is refractory to significant reactivation with 2-PAM In the present study, we modified a guinea pig model (Fleisher and Harris, 1965; Fleisher et al., 1967) . Thus, in that had been used previously to evaluate potential anti-GD exposure, the use of 2-PAM in the model played no role convulsant drugs for the treatment of nerve agent-induced in reducing the levels of free ACh to compete with atropine seizures (McDonough et al., 1999 (McDonough et al., , 2000 McDon-for cholinergic receptors. A higher concentration of atroough, 1999 , 2000 Shih et al., 2003) . Model A had used a pine is therefore required to compete with the excess ACh higher dose of atropine (2.0 mg/kg) and anticonvulsant at synapses. However, VX-inhibited AChE displays neglitreatment was given 5 min after seizure onset, whereas gible aging, and it is readily reactivated by 2-PAM. Bethe refined model B used a lower dose of atropine (0.1 cause of the availability of reactivated AChE by 2-PAM, mg/kg), and anticonvulsant treatment was given immedi-less free ACh is available at the synaptic junction, which in ately after EEG seizure onset. Model B uses the total dose turn requires less atropine for competition at the cholinof atropine and 2-PAM, equivalent to three sets of the ergic receptors. This may also explain the longer seizure nerve agent antidote kit MARK I autoinjectors, and the latency with VX compared with GD. The lower dose of anticonvulsant drug was administrated at the time EEG atropine in model B after administration of VX may have seizure activity started. Thus, it more closely simulates been less effective at blocking ACh receptors as readily as the current medical treatment protocol for immediate mil-the higher atropine dose did (i.e., mass action) in model A itary treatment of a severe nerve agent exposure. Under and thus increase seizure frequency and shorten the seithese conditions, guinea pigs exhibit moderate-to-severe zure onset time. However, even at the lower dose of atrosalivation and lacrimation after seizure, an indication of pine, the latency to seizure onset for VX was still longer insufficient atropine. Salivation and lacrimation were compared with GD (17 versus 8 min). This difference is rarely observed in guinea pigs treated with 2 mg/kg atro-probably due to a difference in physical properties (e.g., pine (McDonough et al., 1999 (McDonough et al., , 2000 McDonough, chemical structure, pK,, and lipid solubility) between 1999, 2000; Shih et al., 2003) . Nevertheless, even with the these two agents, which affects their speed to penetrate 0.1-mg/kg dose of atropine, diazepam, midazolam, and sco-the blood-brain barrier and inhibits brain AChE (Shih et polamine still exhibited excellent anticonvulsant effects al., 2005). There is also the possibility of drug and agent interactions among the administered pretreatment, ther-immediate treatment dose of atropine (0.1 mg/kg) and apy, and the nerve agent. It would be of interest to know 2-PAM (25 mg/kg), seizures occur (100%) in guinea pigs for whether GD and VX when given in the same challenge all of the tested nerve agents after a 2 X LD 5 o challenge. dose would have similar latency to seizure onset in the These exposed subjects exhibit more severe signs of intoxabsence of PB pretreatment and atropine + 2-PAM ther-ication and also have a higher incidence of mortality with apy in our models. This would more closely mimic the case either benzodiazepine compared with benzodiazepine of a terrorist use of nerve agent against civilians, such as treatment and the higher atropine dose. The incidence of the case of the Tokyo subway sarin attacks, where pre-GF-induced coma would be higher. Furthermore, seizure treatment or atropine/oxime/anticonvulsant therapy is not onset time is shorter for GB, GF, and VX. Diazepam, immediately available. The incidence of seizures and other midazolam, and scopolamine are all effective anticonvultoxic signs and the effectiveness of standard medical coun-sant drugs for treating seizures induced by nerve agents; termeasures have not been fully investigated under such midazolam and scopolamine have higher potency than didelayed treatment circumstances.
azepam. An increased dose of midazolam with the lower When the lower dose of atropine was used, the anticon-atropine dose may be required to terminate nerve agentvulsant ED,, values for scopolamine or diazepam (with induced seizure activity. The effectiveness of scopolamine respect to either high or low doses of atropine sulfate) in its anticholinergic and anticonvulsant potency as well were, in general, not changed for GD, GF, and VX. The as survivability remains the same for either atropine dose. exceptions are that scopolamine became less effective All of these phenomena support the notion that atropine in against GA (3-fold) and GB (7-fold), whereas diazepam was itself has an anticonvulsant effect, and the dose of atropine more potent (2-fold) against VR. The anticonvulsant ED 50 given to nerve agent casualties may influence the successvalues of midazolam were, however, increased 3-to 17-fold ful outcomes of survival and long-term neuroprotection. for all of the nerve agents tested when the dose of atropine Thus, the current atropine dose for immediate treatment sulfate was reduced from 2.0 to 0.1 mg/kg. Overall, scopol-may not be optimal against some nerve agents. McDonough JH, MeMonagle J, Copeland TL, Zoeffel LD., and Shih T-M (1999 and Shih T-M ( ) (1999 dose of atropine was used, the absolute anticonvulsant dosComparative evaluation of benzodiazepines for control ofsoman-induced seizures.
age required by midazolam was still lower than that required Arch Toxicol 73:473-478. In conclusion, these findings show that, with the current 303.
